Overview

IMX-110 in Patients With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2021-07-15
Target enrollment:
Participant gender:
Summary
Phase 1 is an open-label, multi-center dose escalation/dose expansion study designed to assess the safety, tolerability and pharmacokinetics (PK) for the recommended phase 2 dose (RP2D) of IMX-110. The RP2D will be evaluated in a further dose expansion Phase 2a study submitted.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Immix Biopharma Australia Pty Ltd